KidneyCompanion

Advanced AI Medical Analysis Report

Patient Information

Name:	Aditya Yogesh Raje	**Age:**	55
Phone:	09699616876	**Blood Type:**	A-
Patient ID:	PRAJE02		
Address:	F-104,TARANGANA RESIDENCY,NEAR KHUTWAD CHOWK, HARPALE WASTI,PHURSUNGI,HADAPSAR, PUNE, MAHARASHTRA, MAHARASHTRA, 412308		
Email:	MARK		

Medications & Dosage

#	Medication Name	Dosage	Frequency	Notes
1	Lisinopril	1-0-1	3days	

Clinical Insights

- Lisinopril is an Angiotensin-Converting Enzyme (ACE) inhibitor commonly prescribed for hypertension, heart failure, and post-myocardial infarction. While ACE inhibitors can be renoprotective in certain stages of Chronic Kidney Disease (CKD) by reducing proteinuria and slowing disease progression, their use requires careful consideration and monitoring, especially regarding kidney function and electrolyte levels. The patient profile indicates 'Has Hypertension: 0', which suggests that if hypertension is not the indication, other reasons for prescribing Lisinopril (e.g., heart failure) are not specified. Furthermore, the prescribed duration of '3 days' for Lisinopril is highly unusual, as it is typically a long-term medication. This short duration warrants clarification regarding the specific clinical goal of this brief course. The absence of critical baseline parameters such as CKD stage, eGFR, potassium, sodium, serum creatinine, and blood urea makes it impossible to assess the appropriateness of initiating Lisinopril and to predict its immediate impact on the patient's renal and electrolyte status.

Risk Assessment

- Without baseline kidney function (eGFR, serum creatinine) and electrolyte levels (potassium, sodium), there is an elevated risk of adverse events associated with Lisinopril. Potential risks include:

- Acute Kidney Injury (AKI): ACE inhibitors can cause a reversible decline in kidney function, especially in patients with pre-existing renal impairment, volume depletion, or concomitant use of NSAIDs.
- Hyperkalemia: Lisinopril can increase serum potassium levels, which is a significant concern in CKD patients who may already have impaired potassium excretion.
- Hypotension: Particularly at initiation or with dose increases, Lisinopril can cause a drop in blood pressure, leading to dizziness or syncope.
- Angioedema and Cough: These are less common but serious side effects of ACE inhibitors. The short 3-day duration might limit the manifestation of some long-term risks but necessitates immediate and close monitoring for acute effects.

Lifestyle & Care Recommendations

- Given the lack of crucial patient data and the unusual prescription duration, the following general educational recommendations are paramount:
- Obtain Baseline Labs: Prior to or immediately upon initiation, comprehensive laboratory tests including eGFR, serum creatinine, potassium, sodium, and blood urea nitrogen (BUN) are essential.
- Blood Pressure Monitoring: Regular monitoring of blood pressure is necessary to assess efficacy and identify hypotension.
- Clarify Indication and Duration: The specific reason for prescribing Lisinopril and the intended duration of therapy should be clearly established. If the 3-day duration is accurate, the rationale for such a short course of a typically chronic medication needs to be understood.
- Patient Education: Patients should be educated about potential side effects (e.g., dizziness, cough) and symptoms requiring immediate medical attention (e.g., swelling of face/throat).

Potential Drug Interactions

- Common drug interactions with Lisinopril include:
- Potassium-Sparing Diuretics/Potassium Supplements: Increased risk of hyperkalemia.
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Can reduce the antihypertensive effect of Lisinopril and increase the risk of renal impairment.
- Lithium: Lisinopril can increase serum lithium levels, leading to lithium toxicity.
- Other Antihypertensive Agents: Concomitant use may lead to additive hypotensive effects.
- Sacubitril/Valsartan (ARNI): Concomitant use is contraindicated due to increased risk of angioedema.

Recommended Follow-up

- Immediate follow-up is crucial, especially given the absence of baseline data and the unusual prescription. Within 1-2 days of initiation, kidney function (eGFR, serum creatinine) and electrolyte levels (potassium) should be re-evaluated to assess for acute changes. Blood pressure should be monitored regularly. Further follow-up frequency will depend on the patient's response, laboratory results, and the clarified long-term treatment plan.

MEDICAL DISCLAIMER

This report is generated using AI analysis of provided prescription data. It is intended for informational and educational purposes only. This analysis does NOT constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.